Kong Yingming, Tai Yanghao, Chen Bin, Zhang Meng, Ji Haoyu, Feng Rongke, Shi Liang, Chen Hao
Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences Tongji Shanxi Hospital, Taiyuan, China.
Basic Medical College, Shanxi Medical University, Taiyuan, China.
Front Cell Infect Microbiol. 2025 Jun 9;15:1607586. doi: 10.3389/fcimb.2025.1607586. eCollection 2025.
Sepsis-associated encephalopathy (SAE) constitutes a significant neurological manifestation of sepsis, characterized by high mortality rates and posing a critical threat to patient outcomes. Magnesium sulfate has multiple effects in the nervous system, including neuroprotection, sedation, anticonvulsant activity, enhanced neuroplasticity, anti - inflammation and promotion of nerve repair. It can regulate calcium homeostasis, exert antioxidant effects, and reduce the release of inflammatory factors, thereby alleviating neuronal damage and neurological deficits. This study integrated MIMIC-IV database and network pharmacology to explore magnesium sulfate's neuroprotective mechanisms and clinical impact on SAE outcomes.
Retrospective data from 4,650 SAE patients in MIMIC-IV 3.0 were analyzed. Propensity score matching balanced covariates. Cox models and Kaplan-Meier curves evaluated magnesium sulfate's association with 28-day all-cause mortality (ACM). Network pharmacology identified magnesium sulfate's core targets and pathways.
4183 patients (89.96%) received magnesium sulfate during ICU, while 467 (10.04%) did not receive. The 28-day ACM in patients with SAE was 11.05%. After propensity score matching participants with and without magnesium sulfate administration had 28-day ACM of 17.29% and 30.42%, respectively (P < 0.001). Magnesium sulfate administration was associated with reduced 28-day ACM. Subgroup analysis revealed this association differed in several stratification. Network pharmacology revealed magnesium sulfate targets TNF, IL6, IL1B and CXCL8, modulating pathways including inflammatory response, immune regulation, and cellular stress.
Magnesium sulfate use correlates with improved SAE survival, particularly those with comorbid chronic obstructive pulmonary disease and acute kidney injury, and using vasoconstrictors, likely through multi-target modulation of inflammatory response and immune regulation. Prospective studies are needed for validation.
脓毒症相关脑病(SAE)是脓毒症的一种重要神经表现,死亡率高,对患者预后构成严重威胁。硫酸镁在神经系统中具有多种作用,包括神经保护、镇静、抗惊厥活性、增强神经可塑性、抗炎和促进神经修复。它可以调节钙稳态,发挥抗氧化作用,并减少炎症因子的释放,从而减轻神经元损伤和神经功能缺损。本研究整合了MIMIC-IV数据库和网络药理学,以探讨硫酸镁对SAE的神经保护机制及其对临床结局的影响。
分析了MIMIC-IV 3.0中4650例SAE患者的回顾性数据。倾向评分匹配平衡协变量。Cox模型和Kaplan-Meier曲线评估硫酸镁与28天全因死亡率(ACM)的相关性。网络药理学确定了硫酸镁的核心靶点和途径。
4183例患者(89.96%)在重症监护病房期间接受了硫酸镁治疗,而467例(10.04%)未接受。SAE患者的28天ACM为11.05%。倾向评分匹配后,接受和未接受硫酸镁治疗的参与者28天ACM分别为17.29%和30.42%(P<0.001)。硫酸镁治疗与降低28天ACM相关。亚组分析显示,这种关联在几个分层中有所不同。网络药理学显示,硫酸镁靶向肿瘤坏死因子(TNF)、白细胞介素6(IL6)、白细胞介素1β(IL1B)和CXC趋化因子配体8(CXCL8),调节包括炎症反应、免疫调节和细胞应激在内的途径。
硫酸镁的使用与SAE患者生存率的提高相关,特别是那些合并慢性阻塞性肺疾病和急性肾损伤以及使用血管收缩剂的患者,可能是通过对炎症反应和免疫调节的多靶点调节。需要进行前瞻性研究以验证。